Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 13, 2010

Primary Completion Date

July 8, 2013

Study Completion Date

July 8, 2013

Conditions
Fabry Disease
Interventions
BIOLOGICAL

Replagal

0.2 mg/kg administered intravenously \[IV\] every other week

Trial Locations (9)

2380

General Hospital Slovenj Gradec, Slovenj Gradec

3050

The Royal Melbourne Hospital, Parkville

22030

O&O Alpan LLC, Fairfax

52242

University of Iowa Hospitals and Clinics, Iowa City

Unknown

1st School of Medicine Charles University, Prague

Instytut Kardiologii, I Klinika Choroby Wiencowej, Warsaw

FI-20520

Turku University Central Hospital, Turku

31-066

Szpital Uniwersytecki w Krakowie, Krakow

M6 8HD

Salford Royal NHS Foundation Trust, Salford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY